Skip to main content

Advertisement

SpringerLink
Log in

BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines

  • Concise Communication
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

Bromodomain and external domain (BET) proteins regulate cell growth, proliferation, cell cycle, and differentiation in various cancers. Therefore, they have emerged as interesting targets. The effect of BET inhibitor on cutaneous T-cell lymphoma (CTCL), however, is yet to be known. Here, we examined the effect of BET inhibitor JQ1 on four cell lines (MyLa, SeAx, Hut78 and HH cells). CTCL cell lines were treated with JQ1 and cell number, cell cycle, frequency of apoptosis, and expressions of CD25, CD30 and CCR4 on the cell surface were evaluated by flow cytometry. Cell surface molecules were also analyzed by quantitative RT-PCR. JQ1 dose-dependently decreased the cell number of CTCL cells through G1 arrest concomitantly with downregulation of c-Myc expression. JQ1 induced senescence in MyLa cells and apoptosis in Hut78 and HH cells. We also showed that JQ1 inhibited tumor growth of HH cells in vivo. Moreover, JQ1 downregulated CD30 and CCR4 expression both on the cell surface and at mRNA levels. Thus, BET bromodomain inhibitor JQ1 may be useful for treatment of CTCL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Belkina AC, Denis GV (2012) BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer 12:465–477

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Braig M, Lee S, Loddenkemper C et al (2005) Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436:660–665

    Article  CAS  PubMed  Google Scholar 

  3. Duvic M, Pinter-Brown LC, Foss FM et al (2015) Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood 125:1883–1889

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Evan G (2012) Cancer. Taking a back door to target Myc. Science 335(6066):293–294

    Article  CAS  PubMed  Google Scholar 

  5. Filippakopoulos P, Qi J, Picaud S et al (2010) Selective inhibition of BET bromodomains. Nature 468:1067–1073

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Fu LL, Tian M, Li X et al (2015) Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. Oncotarget 6:5501–5516

    Article  PubMed  PubMed Central  Google Scholar 

  7. Guenova E, Hoetzenecker W, Rozati S et al (2014) Novel therapies for cutaneous T-cell lymphoma: what does the future hold? Expert Opin Investig Drugs 23:457–467

    Article  CAS  PubMed  Google Scholar 

  8. Kanavaros P, Ioannidou D, Tzardi M et al (1994) Mycosis fungoides: expression of C-myc p62 p53, bcl-2 and PCNA proteins and absence of association with Epstein-Barr virus. Pathol Res Pr 190:767–774

    Article  CAS  Google Scholar 

  9. Kim YH, Tavallaee M, Sundram U et al (2015) Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol 33:3750–3758

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Kitadate A, Ikeda S, Teshima K et al (2016) MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas. Oncogene 35:3692–3704

    Article  CAS  PubMed  Google Scholar 

  11. Maj J, Jankowska-Konsur A, Plomer-Niezgoda E et al (2013) Altered expression of Bcl-2, c-Myc, H-Ras, K-Ras, and N-Ras does not influence the course of mycosis fungoides. Arch Med Sci 9:895–898

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Manfé V, Biskup E, Johansen P et al (2012) MDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous T-cell lymphoma: role of p53. J Investig Dermatol 132(5):1487–1496

    Article  PubMed  Google Scholar 

  13. Olsen E, Duvic M, Frankel A et al (2001) Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19:376–388

    Article  CAS  PubMed  Google Scholar 

  14. Qi J (2014) Bromodomain and extraterminal domain inhibitors (BETi) for cancer therapy: chemical modulation of chromatin structure. Cold Spring Harb Perspect Biol 6:a018663

    Article  PubMed  PubMed Central  Google Scholar 

  15. Sugaya M, Miyagaki T, Ohmatsu H et al (2012) Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. J Dermatol Sci 68:45–51

    Article  CAS  PubMed  Google Scholar 

  16. Willemze R, Jaffe ES, Burg G et al (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768–3785

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan

    Hiroaki Kamijo, Makoto Sugaya, Naomi Takahashi, Tomonori Oka, Tomomitsu Miyagaki, Yoshihide Asano & Shinichi Sato

Authors
  1. Hiroaki Kamijo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Makoto Sugaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naomi Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tomonori Oka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomomitsu Miyagaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshihide Asano
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shinichi Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Makoto Sugaya.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Funding source

This study was supported by Grants from the Ministry of Education, Culture, Sports, and Technology in Japan (16K10146).

Ethical approval

The medical ethical committee of the University of Tokyo approved all described studies, and the study was conducted according to the Declaration of Helsinki Principles.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kamijo, H., Sugaya, M., Takahashi, N. et al. BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines. Arch Dermatol Res 309, 491–497 (2017). https://doi.org/10.1007/s00403-017-1749-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-017-1749-9

Keywords

Search

Navigation